Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists

Area of Science:

• Integrin biology
• Molecular and cellular oncology
• Drug discovery and development

Background:

• Integrins are transmembrane receptors crucial for cell adhesion, motility, and proliferation.
• Their role in cancer, thrombosis, angiogenesis, and osteoporosis makes them significant therapeutic targets.
• Current single-integrin-targeting drugs face challenges due to cancer cell adaptability and resistance.

Purpose of the Study:

• To review the progress of developing multi-targeted integrin antagonists.
• To explore antagonists targeting multiple Arg-Gly-Asp (RGD) binding integrins for anticancer therapy.

Main Methods:

• Review of existing literature on integrin antagonists.
• Focus on antagonists targeting a combination of RGD-binding integrins.
• Analysis of integrin subtypes including αvβ3, αvβ5, αvβ6, αvβ8, α5β1, and αIIbβ3.

Main Results:

• Single-target integrin inhibition can lead to resistance and paradoxical tumor growth.
• Development of antagonists targeting multiple RGD-binding integrins is an emerging strategy.
• This approach shows potential for overcoming drug resistance in cancer therapy.

Conclusions:

• Targeting multiple integrins presents a viable strategy to overcome drug resistance in cancer.
• Combined targeting of RGD-binding integrins offers a more robust therapeutic approach.
• Further development of multi-integrin antagonists is warranted for effective anticancer treatments.